Global Search | Novartis

Hide Filters

Showing 2716 results

Press Release / May 17, 2016

Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis

Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the…
Press Release / May 19, 2016

Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure

Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program…
Press Release / May 18, 2016

Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®* First genomic analysis and 3-year…
Press Release / May 24, 2016

Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label…
Press Release / May 21, 2016

Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals

US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated…
Press Release / Jun 02, 2016

Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)

Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are…
Press Release / May 25, 2016

Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
Press Release / Jun 06, 2016

Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (…
Press Release / Jun 04, 2016

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >…
Press Release / Jun 08, 2016

Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …